Potential role of immunotherapy in advanced non-small-cell lung cancer

Mello, Ramon Andrade De; Veloso, Ana Flávia de Holanda; Catarina, Paulo Esrom; Nadine, Sara; Antoniou, Georgios

doi:10.2147/ott.s90459

Cited by 52 publications

(35 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Normally, PD-1 inhibition is found at the site of the tumor, whereas CTLA-4 occurs primarily in the lymphoid organs [170]. Newer inhibitors have been developed to NSCLC.…”

Section: Therapeutic Approaches In Nsclcmentioning

confidence: 99%

Role of Autophagy and Apoptosis in Non-Small-Cell Lung Cancer

Liu

Pei

Yang³

et al. 2017

IJMS

325

248

View full text Add to dashboard Cite

Non-small-cell lung cancer (NSCLC) constitutes 85% of all lung cancers, and is the leading cause of cancer-related death worldwide. The poor prognosis and resistance to both radiation and chemotherapy warrant further investigation into the molecular mechanisms of NSCLC and the development of new, more efficacious therapeutics. The processes of autophagy and apoptosis, which induce degradation of proteins and organelles or cell death upon cellular stress, are crucial in the pathophysiology of NSCLC. The close interplay between autophagy and apoptosis through shared signaling pathways complicates our understanding of how NSCLC pathophysiology is regulated. The apoptotic effect of autophagy is controversial as both inhibitory and stimulatory effects have been reported in NSCLC. In addition, crosstalk of proteins regulating both autophagy and apoptosis exists. Here, we review the recent advances of the relationship between autophagy and apoptosis in NSCLC, aiming to provide few insights into the discovery of novel pathogenic factors and the development of new cancer therapeutics.

show abstract

“…Normally, PD-1 inhibition is found at the site of the tumor, whereas CTLA-4 occurs primarily in the lymphoid organs [170]. Newer inhibitors have been developed to NSCLC.…”

Section: Therapeutic Approaches In Nsclcmentioning

confidence: 99%

Role of Autophagy and Apoptosis in Non-Small-Cell Lung Cancer

Liu

Pei

Yang³

et al. 2017

IJMS

325

248

View full text Add to dashboard Cite

show abstract

“…More recently, emerging knowledge about some of the mechanisms that govern the complex interaction between tumour cells and the host immune system, prompted a re-discovery of immune-oncology in lung cancer treatment, as well as in other tumours 33 .…”

Section: Advanced Nsclc Treatmentmentioning

confidence: 99%

Lung Cancer Management: where are we in 2017?

Scagliotti¹,

Bironzo²,

Rosell³

2017

BRN

View full text Add to dashboard Cite

“…NSCLC accounts for approximately 85% of lung malignancies [3], and nearly 75% of NSCLC cases are diagnosed in the advanced stage with an estimated 5-year survival rate of 18% in the United States [4]. Immune checkpoint inhibitors have emerged as powerful new therapeutic tools for advanced NSCLC [5,6]. However, although antibodies against programmed death-1 and cytotoxic T lymphocyte associated protein 4 may improve outcomes in a metastatic setting, the overall response rate is less than 45% even in highly molecularly selected patients [5][6][7].…”

Section: Introductionmentioning

confidence: 99%

“…Immune checkpoint inhibitors have emerged as powerful new therapeutic tools for advanced NSCLC [5,6]. However, although antibodies against programmed death-1 and cytotoxic T lymphocyte associated protein 4 may improve outcomes in a metastatic setting, the overall response rate is less than 45% even in highly molecularly selected patients [5][6][7]. This is partly due to the complex strategies adopted by tumor cells to escape the cytotoxicity of the immune system.…”

Section: Introductionmentioning

confidence: 99%

Interleukin-35 Suppresses the Antitumor Activity of T Cells in Patients with Non-Small Cell Lung Cancer

Wang¹,

Zhang²,

Feng³

et al. 2018

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: Interleukin (IL)-35 has immunosuppressive functions in autoimmune diseases, infectious diseases, and certain cancers. However, few studies have focused on its immunoregulatory activity in non-small cell lung cancer (NSCLC). Thus, we investigated the role of IL-35 in the pathogenesis of this disease. Methods: A total of 66 NSCLC patients and 21 healthy individuals were enrolled. IL-35 expression in peripheral blood and bronchoalveolar lavage fluid (BALF) was measured. The modulatory functions of IL-35 on purified CD4⁺ and CD8⁺ T cells from NSCLC patients were investigated in direct and indirect coculture systems with NSCLC cell lines. Results: IL-35 expression was significantly increased in BALF from the tumor site, but not in the peripheral blood of NSCLC patients. IL-35 did not affect the bioactivity including proliferation, cytokine production, cell cycle, and cellular invasion of NSCLC cells. It suppressed responses from type 1 T helper (Th1) and Th17 cells but elevated the regulatory T cell response in cultured CD4⁺ T cells from NSCLC patients, and reduced cytokine-mediated CD4⁺ T cells cytotoxicity to NSCLC cells. Moreover, IL-35 also inhibited cytotoxic gene expression in CD8⁺ T cells from NSCLC, reducing their cytolytic and noncytolytic functions. Conclusion: The results of this study suggest that IL-35 contributes to the dysfunction/exhaustion of T cells and limited antitumor immune responses in NSCLC.

show abstract

Potential role of immunotherapy in advanced non-small-cell lung cancer

Cited by 52 publications

References 55 publications

Role of Autophagy and Apoptosis in Non-Small-Cell Lung Cancer

Role of Autophagy and Apoptosis in Non-Small-Cell Lung Cancer

Lung Cancer Management: where are we in 2017?

Interleukin-35 Suppresses the Antitumor Activity of T Cells in Patients with Non-Small Cell Lung Cancer

Contact Info

Product

Resources

About